Microencapsulation of Leydig Cells: A System for Testosterone Supplementation

Marcelle Machluf, Anna Orsola, Stephen Boorjian, Richard Kershen, Anthony Atala

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The use of testosterone supplementation for elderly men has increased markedly over the last decade due to a recognized gradual decline in serum testosterone, which may lead to decreased bone mass, muscle strength, and libido. Testosterone supplementation is also used widely to treat some forms of erectile dysfunction, androgen deficiency, and infertility. However, long-term exogenous testosterone therapy has been associated with several complications, such as fluid retention, nitrogen retention, and hypertension. Due to these problems, alternate treatment modalities, involving more physiological and longer-acting systems for androgen delivery, have been pursued. Alginate-poly-L-lysine-encapsulated Leydig cell microspheres were used as a novel method for the delivery of testosterone in vivo. Encapsulated Leydig cells, which were stimulated with human chorionic gonadotropin, secreted high levels of testosterone in culture. Unencapsulated cells injected ip or se failed to produce any testosterone levels, even with human chorionic gonadotropin stimulation. Castrated rats that were administered encapsulated Leydig cells ip or sc maintained a serum testosterone level between 0.23 and 0.51 ng/ml. Similar levels of testosterone were obtained for 43 d when the encapsulated Leydig cells were injected sc (0.28-0.48 ng/ml). Approximately 10% of a normal adult rat Leydig cell population was injected into each castrated animal; however, this resulted in serum testosterone levels of up to 40% of normal. Clinically, testosterone is usually delivered for supplementation and not for full replacement therapy. Therefore, the findings of this study suggest that microencapsulated Leydig cells may be a viable option as a therapeutic modality involving testosterone supplementation.

Original languageEnglish (US)
Pages (from-to)4975-4979
Number of pages5
JournalEndocrinology
Volume144
Issue number11
DOIs
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Drug Compounding
Leydig Cells
Testosterone
Chorionic Gonadotropin
Androgens
Serum
Libido
Muscle Strength
Erectile Dysfunction
Therapeutics
Microspheres
Infertility
Nitrogen

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Machluf, M., Orsola, A., Boorjian, S., Kershen, R., & Atala, A. (2003). Microencapsulation of Leydig Cells: A System for Testosterone Supplementation. Endocrinology, 144(11), 4975-4979. https://doi.org/10.1210/en.2003-0411

Microencapsulation of Leydig Cells : A System for Testosterone Supplementation. / Machluf, Marcelle; Orsola, Anna; Boorjian, Stephen; Kershen, Richard; Atala, Anthony.

In: Endocrinology, Vol. 144, No. 11, 11.2003, p. 4975-4979.

Research output: Contribution to journalArticle

Machluf, M, Orsola, A, Boorjian, S, Kershen, R & Atala, A 2003, 'Microencapsulation of Leydig Cells: A System for Testosterone Supplementation', Endocrinology, vol. 144, no. 11, pp. 4975-4979. https://doi.org/10.1210/en.2003-0411
Machluf M, Orsola A, Boorjian S, Kershen R, Atala A. Microencapsulation of Leydig Cells: A System for Testosterone Supplementation. Endocrinology. 2003 Nov;144(11):4975-4979. https://doi.org/10.1210/en.2003-0411
Machluf, Marcelle ; Orsola, Anna ; Boorjian, Stephen ; Kershen, Richard ; Atala, Anthony. / Microencapsulation of Leydig Cells : A System for Testosterone Supplementation. In: Endocrinology. 2003 ; Vol. 144, No. 11. pp. 4975-4979.
@article{752de95df011488588f305ba03699ecc,
title = "Microencapsulation of Leydig Cells: A System for Testosterone Supplementation",
abstract = "The use of testosterone supplementation for elderly men has increased markedly over the last decade due to a recognized gradual decline in serum testosterone, which may lead to decreased bone mass, muscle strength, and libido. Testosterone supplementation is also used widely to treat some forms of erectile dysfunction, androgen deficiency, and infertility. However, long-term exogenous testosterone therapy has been associated with several complications, such as fluid retention, nitrogen retention, and hypertension. Due to these problems, alternate treatment modalities, involving more physiological and longer-acting systems for androgen delivery, have been pursued. Alginate-poly-L-lysine-encapsulated Leydig cell microspheres were used as a novel method for the delivery of testosterone in vivo. Encapsulated Leydig cells, which were stimulated with human chorionic gonadotropin, secreted high levels of testosterone in culture. Unencapsulated cells injected ip or se failed to produce any testosterone levels, even with human chorionic gonadotropin stimulation. Castrated rats that were administered encapsulated Leydig cells ip or sc maintained a serum testosterone level between 0.23 and 0.51 ng/ml. Similar levels of testosterone were obtained for 43 d when the encapsulated Leydig cells were injected sc (0.28-0.48 ng/ml). Approximately 10{\%} of a normal adult rat Leydig cell population was injected into each castrated animal; however, this resulted in serum testosterone levels of up to 40{\%} of normal. Clinically, testosterone is usually delivered for supplementation and not for full replacement therapy. Therefore, the findings of this study suggest that microencapsulated Leydig cells may be a viable option as a therapeutic modality involving testosterone supplementation.",
author = "Marcelle Machluf and Anna Orsola and Stephen Boorjian and Richard Kershen and Anthony Atala",
year = "2003",
month = "11",
doi = "10.1210/en.2003-0411",
language = "English (US)",
volume = "144",
pages = "4975--4979",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Microencapsulation of Leydig Cells

T2 - A System for Testosterone Supplementation

AU - Machluf, Marcelle

AU - Orsola, Anna

AU - Boorjian, Stephen

AU - Kershen, Richard

AU - Atala, Anthony

PY - 2003/11

Y1 - 2003/11

N2 - The use of testosterone supplementation for elderly men has increased markedly over the last decade due to a recognized gradual decline in serum testosterone, which may lead to decreased bone mass, muscle strength, and libido. Testosterone supplementation is also used widely to treat some forms of erectile dysfunction, androgen deficiency, and infertility. However, long-term exogenous testosterone therapy has been associated with several complications, such as fluid retention, nitrogen retention, and hypertension. Due to these problems, alternate treatment modalities, involving more physiological and longer-acting systems for androgen delivery, have been pursued. Alginate-poly-L-lysine-encapsulated Leydig cell microspheres were used as a novel method for the delivery of testosterone in vivo. Encapsulated Leydig cells, which were stimulated with human chorionic gonadotropin, secreted high levels of testosterone in culture. Unencapsulated cells injected ip or se failed to produce any testosterone levels, even with human chorionic gonadotropin stimulation. Castrated rats that were administered encapsulated Leydig cells ip or sc maintained a serum testosterone level between 0.23 and 0.51 ng/ml. Similar levels of testosterone were obtained for 43 d when the encapsulated Leydig cells were injected sc (0.28-0.48 ng/ml). Approximately 10% of a normal adult rat Leydig cell population was injected into each castrated animal; however, this resulted in serum testosterone levels of up to 40% of normal. Clinically, testosterone is usually delivered for supplementation and not for full replacement therapy. Therefore, the findings of this study suggest that microencapsulated Leydig cells may be a viable option as a therapeutic modality involving testosterone supplementation.

AB - The use of testosterone supplementation for elderly men has increased markedly over the last decade due to a recognized gradual decline in serum testosterone, which may lead to decreased bone mass, muscle strength, and libido. Testosterone supplementation is also used widely to treat some forms of erectile dysfunction, androgen deficiency, and infertility. However, long-term exogenous testosterone therapy has been associated with several complications, such as fluid retention, nitrogen retention, and hypertension. Due to these problems, alternate treatment modalities, involving more physiological and longer-acting systems for androgen delivery, have been pursued. Alginate-poly-L-lysine-encapsulated Leydig cell microspheres were used as a novel method for the delivery of testosterone in vivo. Encapsulated Leydig cells, which were stimulated with human chorionic gonadotropin, secreted high levels of testosterone in culture. Unencapsulated cells injected ip or se failed to produce any testosterone levels, even with human chorionic gonadotropin stimulation. Castrated rats that were administered encapsulated Leydig cells ip or sc maintained a serum testosterone level between 0.23 and 0.51 ng/ml. Similar levels of testosterone were obtained for 43 d when the encapsulated Leydig cells were injected sc (0.28-0.48 ng/ml). Approximately 10% of a normal adult rat Leydig cell population was injected into each castrated animal; however, this resulted in serum testosterone levels of up to 40% of normal. Clinically, testosterone is usually delivered for supplementation and not for full replacement therapy. Therefore, the findings of this study suggest that microencapsulated Leydig cells may be a viable option as a therapeutic modality involving testosterone supplementation.

UR - http://www.scopus.com/inward/record.url?scp=0242468474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242468474&partnerID=8YFLogxK

U2 - 10.1210/en.2003-0411

DO - 10.1210/en.2003-0411

M3 - Article

C2 - 12960073

AN - SCOPUS:0242468474

VL - 144

SP - 4975

EP - 4979

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 11

ER -